Kurosawa and the Shakespearean Moral Vision

Coming to terms with a film such as Kurosawa\u27s Throne of Blood (1957) is crucial to the whole question of Shakespeare on film. It not only involves the study of a particular text and film and how the film director has handled Shakespeare\u27s plot, character, and meaning, but it also focuses on larger cinematic issues concerning acting, visual image, and metaphor on film, and the manner in which complex ideas can be expressed visually. Peter Brook has observed that Throne of Blood is perhaps the only true masterpiece inspired by Shakespeare, but it cannot properly be considered Shakespeare because it doesn\u27t use the text. Michael Mullin has put it succinctly by suggesting that Kurosawa\u27s film is a thing in itself

Brief Note: Smooth-billed Ani (Crotophaga ani L.), a New Species of Bird for Ohio

Author Institution: Department of Biology, John Carroll University ; Department of Vertebrate Zoology, The Cleveland Museum of Natural HistoryA smooth-billed ani (Crotophaga ani L.) is reported from Ohio for the first time. The specimen (CMNH 68471) also represents the first inland state record for the United States. Confirmation of specific identity was obtained because of the significance of the record and some equivocal characteristics of the specimen. Care in field identification of extralimital anis is suggested

The Evolution of the Stellar Hosts of Radio Galaxies

We present new near-infrared images of z>0.8 radio galaxies from the flux-limited 7C-III sample of radio sources for which we have recently obtained almost complete spectroscopic redshifts. The 7C objects have radio luminosities about 20 times fainter than 3C radio galaxies at a given redshift. The absolute magnitudes of the underlying host galaxies and their scale sizes are only weakly dependent on radio luminosity. Radio galaxy hosts at z~2 are significantly brighter than the hosts of radio-quiet quasars at similar redshifts and the model AGN hosts of Kauffmann & Haehnelt (2000). There is no evidence for strong evolution in scale size, which shows a large scatter at all redshifts. The hosts brighten significantly with redshift, consistent with the passive evolution of a stellar population that formed at z>~3. This scenario is consistent with studies of host galaxy morphology and submillimeter continuum emission, both of which show strong evolution at z>~2.5. The lack of a strong ``redshift cutoff'' in the radio luminosity function to z>4 suggests that the formation epoch of the radio galaxy host population lasts >~1Gyr from z>~5 to z~3. We suggest these facts are best explained by models in which the most massive galaxies and their associated AGN form early due to high baryon densities in the centres of their dark matter haloes.Comment: To appear in A

Improvements in Awareness and Testing Have Led to a Threefold Increase Over 10 Years in the Identification of Monogenic Diabetes in the U.K

This is the author accepted manuscript. The final version is available from the American Diabetes Association via the DOI in this recordAims/hypothesis: Maturity Onset Diabetes of the Young (MODY) is a rare monogenic form of diabetes. In 2009, >80% of UK cases were estimated to be misdiagnosed. Since then, there have been a number of initiatives to improve the awareness and detection of MODY including education initiatives (Genetic Diabetes Nurse (GDN) programme), the MODY probability calculator, and targeted next generation sequencing (tNGS). We aimed to examine how the estimated prevalence of MODY, and other forms of monogenic diabetes diagnosed outside the neonatal period, has changed over time and how the initiatives have impacted case finding. Research design and Methods: UK referrals for genetic testing for monogenic diabetes diagnosed >1y of age from 01/01/1996 to 31/12/2019 were examined. Positive-test rates were compared for referrals reporting involvement of the GDNs/MODY calculator with those that did not. Results: A diagnosis of monogenic diabetes was confirmed in 3860 individuals, >3-fold higher than 2009 (01/01/1996-28/02/2009; n=1177). Median age at diagnosis in probands was 21y. GDN involvement was reported in 21% of referrals; these referrals had a higher positive-test rate than those without GDN involvement (32% v 23%, p<0.001). MODY calculator usage was indicated on 74% of eligible referrals since 2014; these referrals had a higher positive-test rate than those not using the calculator (33% v 25%, p=0.001). 410 (10.6%) cases were identified through tNGS. Monogenic diabetes prevalence was estimated to be 248 cases/million (double that estimated in 2009 due to increased case-finding). 3 Conclusions: Since 2009, referral rates and case diagnosis have increased three-fold. This is likely to be the consequence of tNGS, GDN education and the MODY calculator

A Promiscuous Bacterial P450: The Unparalleled Diversity of BM3 in Pharmaceutical Metabolism

CYP102A1 (BM3) is a catalytically self-sufficient flavocytochrome fusion protein isolated from Bacillus megaterium, which displays similar metabolic capabilities to many drug-metabolizing human P450 isoforms. BM3′s high catalytic efficiency, ease of production and malleable active site makes the enzyme a desirable tool in the production of small molecule metabolites, especially for compounds that exhibit drug-like chemical properties. The engineering of select key residues within the BM3 active site vastly expands the catalytic repertoire, generating variants which can perform a range of modifications. This provides an attractive alternative route to the production of valuable compounds that are often laborious to synthesize via traditional organic means. Exten-sive studies have been conducted with the aim of engineering BM3 to expand metabolite pro-duction towards a comprehensive range of drug-like compounds, with many key examples found both in the literature and in the wider industrial bioproduction setting of desirable oxy-metabolite production by both wild-type BM3 and related variants. This review covers the past and current research on the engineering of BM3 to produce drug metabolites and highlights its crucial role in the future of biosynthetic pharmaceutical production

Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1

The rise in multidrug resistant (MDR) cases of tuberculosis (TB) has led to the need for the development of TB drugs with different mechanisms of action. The genome sequence of Mycobacterium tuberculosis (Mtb) revealed twenty different genes coding for cytochrome P450s. CYP121A1 catalyzes a C-C crosslinking reaction of dicyclotyrosine (cYY) producing mycocyclosin and current research suggests that either mycocyclosin is essential or the overproduction of cYY is toxic to Mtb. A series of 1,4-dibenzyl-2-imidazol-1-yl-methylpiperazine derivatives were designed and synthesised as cYY mimics. The derivatives substituted in the 4-position of the phenyl rings with halides or alkyl group showed promising antimycobacterial activity (MIC 6.25 μg/mL), with the more lipophilic branched alkyl derivatives displaying optimal binding affinity with CYP121A1 (iPr KD = 1.6 μM; tBu KD = 1.2 μM). Computational studies revealed two possible binding modes within the CYP121A1 active site both of which would effectively block cYY from binding

A Promiscuous Bacterial P450: The Unparalleled Diversity of BM3 in Pharmaceutical Metabolism

From MDPI via Jisc Publications RouterHistory: accepted 2021-10-12, pub-electronic 2021-10-21Publication status: PublishedFunder: Biotechnology and Biological Sciences Research Council; Grant(s): BB/M011208/1CYP102A1 (BM3) is a catalytically self-sufficient flavocytochrome fusion protein isolated from Bacillus megaterium, which displays similar metabolic capabilities to many drug-metabolizing human P450 isoforms. BM3′s high catalytic efficiency, ease of production and malleable active site makes the enzyme a desirable tool in the production of small molecule metabolites, especially for compounds that exhibit drug-like chemical properties. The engineering of select key residues within the BM3 active site vastly expands the catalytic repertoire, generating variants which can perform a range of modifications. This provides an attractive alternative route to the production of valuable compounds that are often laborious to synthesize via traditional organic means. Extensive studies have been conducted with the aim of engineering BM3 to expand metabolite production towards a comprehensive range of drug-like compounds, with many key examples found both in the literature and in the wider industrial bioproduction setting of desirable oxy-metabolite production by both wild-type BM3 and related variants. This review covers the past and current research on the engineering of BM3 to produce drug metabolites and highlights its crucial role in the future of biosynthetic pharmaceutical production

Frequentist Interpretation of Probability

Three series of azole piperazine derivatives that mimic dicyclotyrosine (cYY), the natural substrate of the essential Mycobacterium tuberculosis cytochrome P450 CYP121A1, were prepared and evaluated for binding affinity and inhibitory activity (MIC) against M. tuberculosis. Series A replaces one phenol group of cYY with a C3-imidazole moiety, series B includes a keto group on the hydrocarbon chain preceding the series A imidazole, whilst series C explores replacing the keto group of the piperidone ring of cYY with a CH2-imidazole or CH2-triazole moiety to enhance binding interaction with the heme of CYP121A1. The series displayed moderate to weak type II binding affinity for CYP121A1, with the exception of series B 10a, which displayed mixed type I binding. Of the three series, series C imidazole derivatives showed the best, although modest, inhibitory activity against M. tuberculosis (17d MIC = 12.5 μg/mL, 17a 50 μg/mL). Crystal structures were determined for CYP121A1 bound to series A compounds 6a and 6b that show the imidazole groups positioned directly above the haem iron with binding between the haem iron and imidazole nitrogen of both compounds at a distance of 2.2 Å. A model generated from a 1.5 Å crystal structure of CYP121A1 in complex with compound 10a showed different binding modes in agreement with the heterogeneous binding observed. Although the crystal structures of 6a and 6b would indicate binding with CYP121A1, the binding assays themselves did not allow confirmation of CYP121A1 as the target

Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma

BackgroundWe sought to describe targeted DNA sequencing data of persistent/recurrent laryngeal squamous cell carcinoma (LSCC) and to compare gene‐specific alteration frequencies with that of primary, untreated LSCC specimens from The Cancer Genome Atlas (TCGA).MethodsThe tumors of 21 patients with persistent/recurrent LSCC were subjected to targeted DNA sequencing using the Ion AmpliSeq Comprehensive Cancer Panel. Gene‐specific alteration frequencies were compared (Chi‐Square test) to primary, untreated LSCC sequencing data from TCGA using the cBioPortal platform.ResultsPersistent/recurrent LSCC was characterized by a high rate of inactivating alterations in TP53 (38.1%) and CDKN2A (33%), amplification events of CCND1 (19.1%), and ERBB2 (14.3%), and NOTCH1 (19.1%) mutations. Comparison of primary vs persistent/recurrent LSCC revealed significant differences in alteration frequencies of eight critical genes: BAP1, CDKN2A, DCUN1D1, MSH2, MTOR, PIK3CA, TET2, and TP53.ConclusionsOur results provide preliminary support for a distinct mutational profile of persistent/recurrent LSCC that requires validation in larger cohorts.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/147873/1/hed25444.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/147873/2/hed25444_am.pd